Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 6Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 6CNS 2Other solid neoplasm 1Other hematologic neoplasm 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Uveal Melanoma 1Melanoma 1

Interventions

pembrolizumab 65Nivolumab 59Ipilimumab 33Cyclophosphamide 23Specimen Handling 16Magnetic Resonance Spectroscopy 15Biopsy 15relatlimab 13fludarabine 13cemiplimab 13Opdualag 12Blood Specimen Collection 11binimetinib 10aldesleukin 9Radiosurgery 9Interleukin-2 9encorafenib 8atezolizumab 7Immunotherapy 7tebentafusp 6mogamulizumab 6fludarabine phosphate 6Temozolomide 6Surgical Procedures, Operative 6Paclitaxel 6Immunoglobulin G 6CTLA-4 Antigen 6Aminolevulinic Acid 6Radiotherapy 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carmustine × Dermatologic × Clear all
NCT06626516 2025-11-28

Tebentafusp-tebn With LDT in Metastatic UM

Thomas Jefferson University

Phase 1/2 Recruiting
109 enrolled
Dermatologic

Uveal Melanoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡